Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAC-PTLD: N-acetylcysteine to Prevent Post Tuberculosis Lung Disease
NCT06909799Recruiting
- Sponsor
- Aurum Institute
- Start
- Apr 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of acetylcysteine in Tuberculosis (TB) (2 arms), sponsored by Aurum Institute. Primary endpoint: Forced Expiratory Volume in 1 second percentage of predicted at 12 months. Started Apr 2025; status: recruiting.
02
Drugs
acetylcysteine
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT06909799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06909799.